Home/Filings/4/0001213900-24-017449
4//SEC Filing

Cactus Healthcare Management LP 4

Accession 0001213900-24-017449

CIK 0001865861other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 3:27 PM ET

Size

11.0 KB

Accession

0001213900-24-017449

Insider Transaction Report

Form 4
Period: 2024-02-23
Transactions
  • Sale

    Class A ordinary shares

    2024-02-232,530,000632,501 total
  • Sale

    Warrants to purchase Class A ordinary shares

    2024-02-233,893,334973,333 total
    Exercise: $11.50Class A ordinary shares (3,893,334 underlying)
Transactions
  • Sale

    Class A ordinary shares

    2024-02-232,530,000632,501 total
  • Sale

    Warrants to purchase Class A ordinary shares

    2024-02-233,893,334973,333 total
    Exercise: $11.50Class A ordinary shares (3,893,334 underlying)
Footnotes (5)
  • [F1]The transaction reported herein consists of the private sale by Cactus Healthcare Management LP of (i) 2,530,000 founders shares (consisting of 2,529,999 Class A ordinary shares and one Class B ordinary share which may be converted into a Class A ordinary share upon election by the holder thereof, and therefore treated for purposes hereof as a Class A ordinary share) and (ii) 3,893,334 warrants to purchase Class A ordinary shares.
  • [F2]The aggregate sales price received by the reporting persons for all securities sold in the transaction (the founders shares and the warrants) reported herein was $1.00, which is an effective price of less than $0.00 (i) per share and (ii) per warrant.
  • [F3]The securities reported in this row are held of record by Cactus Healthcare Management LP (the "Cactus sponsor"). Cactus Healthcare Management LLC (the "Cactus sponsor GP") serves as the sole general partner of the Cactus sponsor and directs voting and investment decisions made by the Cactus sponsor with respect to the subject shares. The Cactus sponsor GP is owned equally by Hibotan LLC (an affiliate of Israel Biotech Fund), Kalistcare Limited (an affiliate of Consensus Business Group) and Clal Biotechnology Industries Cactus Ltd. (an affiliate of Clal Biotechnology Industries Ltd.), each of which holds a 33.33% equity interest in the Cactus sponsor GP. The Cactus sponsor GP does not possess a pecuniary interest with respect to the subject shares and therefore disclaims beneficial ownership thereof.
  • [F4]The warrants become exercisable 30 days after the Issuer completes its initial business combination (which date is not known currently).
  • [F5]The warrants expire on the 5th year anniversary of the Issuer's initial business combination (which date is not known currently).

Documents

1 file

Issuer

Cactus Acquisition Corp. 1 Ltd

CIK 0001865861

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001918110

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 3:27 PM ET
Size
11.0 KB